Jason J. Luke, MD, FACP
The combination of nivolumab (Opdivo), a PD-1 inhibitor, and BMS-986205, a novel IDO inhibitor, generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers in an early-phase clinical trial that helps fuel growing interest in regimens that target the 2 immune checkpoint pathways.
“The IDO pathway is an important immunosuppressant pathway that is upregulated in the context of a productive interferon gamma–associated tumor microenvironment,” Luke said in the interview. “We initially thought of that as PD-L1 alone but we’re learning that most often when PD-L1 gets upregulated IDO gets upregulated as well and can act as a secondary immunologic or metabolic checkpoint to slow down T cells, even if you block PD-1.”
... to read the full story